Eli Lilly and Novo Nordisk have reached a significant agreement with the Trump administration to reduce the prices of their obesity drugs. This deal not only provides tariff relief but also ensures that Medicare patients will have better access to these essential medications at a lower cost. President Trump highlighted the importance of this initiative during a recent address, emphasizing its potential to improve healthcare affordability for many Americans. This move is crucial as it addresses the rising concerns over obesity and the financial burden of related treatments.